The framework the new FDA leaders laid out on Tuesday raised small and big questions about the regulatory process, vaccine access, and medical ethics.

The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the virus, and those older than age 65.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

Peter A. McCullough, a former cardiologist who promoted unproven treatments like ivermectin and hydroxychloroquine at the height of the pandemic, posted a video to Instagram claiming that Biden’s cancer was “turbo cancer.”

A new strain of COVID-19 gaining traction overseas is now being detected in the United States, according to health officials tracking the virus. Airport screenings have identified cases of the NB.1.8.

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

A Phoenix doctor weighs in on the potential impact of FDA plans to limit COVID booster access to high-risk groups, raising cost and care concerns.